A Phase 2 interventional study of evinacumab and Placebo in Severe Hypertriglyceridemia (sHTG), sponsored by Regeneron Pharmaceuticals. Completed at 17 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-16.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.
Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 70th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2018, is one of 45 in phase 2, and was the 107th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 1 more country
Ages 18+
Marea Therapeutics · Sites in United States
Ages 18–75
The Miriam Hospital · Sites in United States
Ages 18–69
Marea Therapeutics · Sites in United States, Australia, Canada and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 51 · Phase 3 30 · Phase 4 13
First in 1977; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 52 across the 145 interventional studies, 130 across the 3 observational. Of the 124 that completed or were terminated, 57 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 150 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 5 studies filed under Hypertriglyceridemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertriglyceridemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT05464784MediciNovaMN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | 2026-12-31 |
| NCT07269210Eli Lilly and CompanyA Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | 2027-03 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertriglyceridemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: evinacumab
Drug: Placebo
Administered by Intravenous (IV)
Also known as: REGN1500
Administered by Intravenous (IV)
Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants
For participants randomized to evinacumab treatment group, baseline (Week 0) TG was defined as the geometric mean of all available TG results at day -28, day -14 and week 0; for participants randomized to placebo treatment group, baseline (Week 12) TG was defined as the geometric mean of all available TG results at weeks 6, 8, and 12.
Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group
Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab overall group during DBTP and SBTP was reported.
Time frame: DBTP: Baseline, Weeks 2, 4, 6, 8, 12; SBTP: Weeks 16, 20, and 24
Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3
Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab in actual cohorts 1, 2, and 3 participants were reported.
Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, and 24
Change From Baseline in Total Score of Participants Reported Abdominal and Gastrointestinal (GI) Symptoms Using Hypertriglyceridemia and Acute Pancreatitis Symptom Scale (HAP-SS)
HAP-SS: 19-item measure of symptoms with a 24-hour recall period. 4 pain items were captured on 0-10-point severity NRS, each scored 0 (No pain) to 10 (Worst possible pain), while 15 non-pain items captured on 5-point frequency Likert scale, each scored from 1 (None of the time) to 5 (All of the time). Pain domain 4 items: stomach pain average, worst stomach pain, worst back pain, stomach pain after eating (score range: 0 to 40). Abdominal symptoms domain 6 items: bloated, nausea, vomiting, passed excessive gas, diarrhea, light-colored or greasy stool (score range: 6 to 30). Physical symptoms domain 5 items: fever, insomnia, excessive sweating, dizziness, racing heart rate (score range 5 to 25). Other symptoms domain 4 items: fatigue, loss of appetite, hungry after eating, felt full after eating a small amount (score range 4 to 20). All items were transformed on to total score ranges from 0 (no symptoms) to 100 (severe symptoms). Negative change indicates better condition.
Time frame: Baseline, Week 12 (DBTP), Week 24 (SBTP)
Change From Baseline in Total Score of Participants Reported Dietary Behavior Questionnaire (HAP-DB)
Dietary habits and impact were measured by the Hypertriglyceridemia and Acute Pancreatitis Dietary Behavior (HAP-DB) questionnaire, a 6- item measure of dietary behavior that had a 24-hour recall period using a 5-point frequency Likert scale (1= None of the time to 5= All of the time) and a dietary impact total score, ranging from 6 (no impact) to 30 (severe impact). The six HAP-DB items were: 1 -amount of food eaten), 2 -fatty or greasy food), 3 -carbohydrates), i4 (-sugar or sugary foods), 5 -alcohol intake), 6 -skipped meal). The total score was calculated as the sum of the six item scores and then transformed to a 0-100 score, where lower score indicates less of an issue with dietary behaviors. Transformed score = 100 \* (score - minimum possible score) / (maximum - minimum possible score). Change from baseline in total score of participants reported daily dietary habits and impact questionnaire during DBTP and SBTP was reported.
Time frame: Baseline, Week 12 (DBTP), Week 24 (SBTP)
DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through 18F-2-Fluoro-2-Deoxy-D Glucose Positron Emission Tomography (18F-FDG-PET) Imaging Following 12 Weeks of Treatment With Evinacumab Assessed by 18F-FDG SUVmax and SUVmean
18F-FDG-PET is a molecular imaging modality that has demonstrated high sensitivity in the in vivo detection of glycolytic tissues, including tumors and inflammatory foci. 18F-FDG PET has been applied in a clinical setting to the assessment of inflammation for a variety of indications, including auto immune pancreatitis, atherosclerosis and infection. 18F-FDG-PET was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Here, SUVmax was standardized uptake values maximum and SUVmean was mean standardized uptake values were reported.
Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) Following 12 Weeks of Treatment With Evinacumab Assessed by Apparent Diffusion Coefficient (ADC)
In DW-MRI the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 cubic millimeter (mm\^3). Normal pancreas ADCs were considered as (1.77±0.32)\*103 square-millimeters per second (mm\^2/sec) while acute pancreatitis ADCs were (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring projected inflammatory changes in pancreas. DW-MRI was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Change from baseline in degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab assessed by ADC was reported.
Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
SBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC
In DW-MRI, the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 mm\^3. Normal pancreas ADCs were considered as (1.77±0.32)\*103 mm\^2/sec while acute pancreatitis ADCs are (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring the projected inflammatory changes in the pancreas. Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab assessed by ADC was reported.
Time frame: Baseline (Week 0 DBTP), Week 24 (SBTP)
Total Evinacumab Concentration in Serum
Concentrations of total evinacumab in serum by time and DBTP treatment group reported
Time frame: Up to 44 weeks
Total Angiopoietin-like (ANGPTL3) Concentration in Serum
Concentrations of total ANGPTL3 in serum by time and DBTP treatment group reported
Time frame: Up to 44 weeks
Number of Participants With Antidrug Antibodies (ADA)
ADA were classified as the following: 1) Negative any time (negative in ADA assay at all time points); 2) Pre-existing immunoreactivity (ADA positive response at baseline with all post treatment ADA results negative or ADA positive response at baseline with all post treatment responses less than 9-fold of baseline titer levels); 3) Treatment-boosted Response (ADA positive response in assay post first dose that is at least 9-fold over baseline titer levels, when baseline results were positive); 4) Treatment-emergent ADA response (ADA positive response post first dose, when baseline results were negative or missing). Number of participants with ADA by DBTP treatment group reported.
Time frame: Up to 44 weeks
DBTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the DBTP reported.
Time frame: From first dose of DB treatment to day of last dose of DB treatment + 24 weeks (if not proceeding to SBTP) or up to day before first dose of SB treatment in SBTP
SBTP: Number of Participants With TEAEs and Serious TEAEs
TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the SBTP reported.
Time frame: From day of first SB study treatment to day of last SB treatment + 24 weeks
Number of Participants With Liver Function Laboratory Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin
The number of participants with laboratory abnormalities in ALT, AST, ALP, and total bilirubin that fell into the pre-defined potentially clinically significant value (PCSV) categories reported: ALT: greater than (\>)2 upper limit of normal (ULN) and baseline (BL) less than or equal to (\<=) 2 ULN, less than (\>) 3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline ≤ 10 ULN, \>20 ULN and baseline \<= 20 ULN; AST: \>2 ULN and baseline ≤ 2 ULN, \>3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline \<= 10 ULN, \>20 ULN and baseline \<= 20 ULN; ALP: \> 1.5 ULN and baseline \<= 1.5 ULN; Total Bilirubin (TB): \> 1.5 ULN and baseline \<= 1.5 ULN, \> 2 ULN and baseline \<= 2 ULN.
Time frame: Baseline up to 44 weeks
A total of 17 centers enrolled participants in Italy, Canada, the United Kingdom of Great Britain and Northern Ireland, and the United States.
| Milestone | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Evinacumab 15 mg/kg (SBTP) |
|---|---|---|---|
| Started | 17 | 35 | 0 |
| Treated | 16 | 35 | 0 |
| Actual cohort 1 | 5 | 12 | 0 |
| Actual cohort 2 | 6 | 9 | 0 |
| Actual cohort 3 | 5 | 14 | 0 |
| Completed | 15 | 32 | 0 |
| Not completed | 2 | 3 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 |
| Milestone | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Evinacumab 15 mg/kg (SBTP) |
|---|---|---|---|
| Started | 0 | 0 | 47 |
| Treated | 0 | 0 | 47 |
| Actual cohort 1: db placebo to sb evinacumab | 0 | 0 | 4 |
| Actual cohort 1: db evinacumab to sb evinacumab | 0 | 0 | 11 |
| Actual cohort 2: db placebo to sb evinacumab | 0 | 0 | 6 |
| Actual cohort 2: db evinacumab to sb evinacumab | 0 | 0 | 9 |
| Actual cohort 3: db placebo to sb evinacumab | 0 | 0 | 5 |
| Actual cohort 3: db evinacumab to sb evinacumab | 0 | 0 | 12 |
| Completed | 0 | 0 | 43 |
| Not completed | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
For participants randomized to evinacumab treatment group, baseline (Week 0) TG was defined as the geometric mean of all available TG results at day -28, day -14 and week 0; for participants randomized to placebo treatment group, baseline (Week 12) TG was defined as the geometric mean of all available TG results at weeks 6, 8, and 12.
| Percent Change | Actual Cohort 3: DB Placebo/SB Evinacumab IV 15mg/kg Q4W | Actual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants | 19.2 ± 99.1 | -37.2 ± 42.9 |
Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab overall group during DBTP and SBTP was reported.
| Percent Change | Placebo Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (SBTP) |
|---|---|---|---|
| Percent change at Week 2 | 1.99 ± 45.687 | -51.38 ± 33.160 | — |
| Percent change at Week 4 | -3.52 ± 41.029 | -43.70 ± 39.119 | — |
| Percent change at Week 6 | 92.56 ± 262.368 | -52.69 ± 40.214 | — |
| Percent change at Week 8 | 4.83 ± 38.941 | -32.86 ± 64.787 | — |
| Percent change at Week 12 | 17.47 ± 47.610 | -42.03 ± 61.086 | — |
| Percent change at Week 16 | — | — | -39.23 ± 46.026 |
| Percent change at Week 20 | — | — | -38.09 ± 49.070 |
| Percent change at Week 24 | — | — | -35.86 ± 65.011 |
Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab in actual cohorts 1, 2, and 3 participants were reported.
| Percent Change | Actual Cohort 1: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Actual Cohort 2: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Actual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W |
|---|---|---|---|
| Percent change at Week 2 | -28.3 (-40.3 to -6.5) | -77.5 (-81.2 to -58.9) | -74.4 (-84.2 to -37.1) |
| Percent change at Week 4 | -19.0 (-69.6 to -2.7) | -48.0 (-76.2 to -29.2) | -70.3 (-83.4 to -50.2) |
| Percent change at Week 6 | -47.1 (-59.1 to -5.6) | -84.6 (-85.7 to -61.3) | -71.3 (-87.0 to -39.5) |
| Percent change at Week 8 | -29.5 (-72.0 to 4.8) | -69.2 (-72.2 to -58.4) | -62.5 (-84.8 to 48.0) |
| Percent change at Week 12 | -27.7 (-68.5 to 2.2) | -64.8 (-84.5 to -41.8) | -81.7 (-90.5 to -21.7) |
| Percent change at Week 16 | -16.2 (-56.7 to 29.3) | -71.3 (-80.8 to -57.1) | -80.4 (-87.2 to -37.3) |
| Percent change at Week 20 | -37.2 (-49.9 to -8.8) | -65.5 (-70.2 to -45.8) | -75.7 (-88.1 to -6.6) |
| Percent change at Week 24 | -7.7 (-31.8 to 9.1) | -75.7 (-82.3 to -57.1) | -71.4 (-86.5 to -54.0) |
HAP-SS: 19-item measure of symptoms with a 24-hour recall period. 4 pain items were captured on 0-10-point severity NRS, each scored 0 (No pain) to 10 (Worst possible pain), while 15 non-pain items captured on 5-point frequency Likert scale, each scored from 1 (None of the time) to 5 (All of the time). Pain domain 4 items: stomach pain average, worst stomach pain, worst back pain, stomach pain after eating (score range: 0 to 40). Abdominal symptoms domain 6 items: bloated, nausea, vomiting, passed excessive gas, diarrhea, light-colored or greasy stool (score range: 6 to 30). Physical symptoms domain 5 items: fever, insomnia, excessive sweating, dizziness, racing heart rate (score range 5 to 25). Other symptoms domain 4 items: fatigue, loss of appetite, hungry after eating, felt full after eating a small amount (score range 4 to 20). All items were transformed on to total score ranges from 0 (no symptoms) to 100 (severe symptoms). Negative change indicates better condition.
| Score on a Scale | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg (DBTP) | Evinacumab IV 15mg/kg (SBTP) |
|---|---|---|---|
| DBTP: Change at Week 12 | -0.69 ± 6.930 | -0.74 ± 5.102 | — |
| SBTP: Change at Week 24 | — | — | -0.12 ± 5.033 |
Dietary habits and impact were measured by the Hypertriglyceridemia and Acute Pancreatitis Dietary Behavior (HAP-DB) questionnaire, a 6- item measure of dietary behavior that had a 24-hour recall period using a 5-point frequency Likert scale (1= None of the time to 5= All of the time) and a dietary impact total score, ranging from 6 (no impact) to 30 (severe impact). The six HAP-DB items were: 1 -amount of food eaten), 2 -fatty or greasy food), 3 -carbohydrates), i4 (-sugar or sugary foods), 5 -alcohol intake), 6 -skipped meal). The total score was calculated as the sum of the six item scores and then transformed to a 0-100 score, where lower score indicates less of an issue with dietary behaviors. Transformed score = 100 \* (score - minimum possible score) / (maximum - minimum possible score). Change from baseline in total score of participants reported daily dietary habits and impact questionnaire during DBTP and SBTP was reported.
| Score on a Scale | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg (DBTP) | Evinacumab IV 15mg/kg (SBTP) |
|---|---|---|---|
| DBTP: Change at Week 12 | -2.267 ± 5.5897 | 2.021 ± 15.2152 | — |
| SBTP: Change at Week 24 | — | — | -1.255 ± 7.7864 |
18F-FDG-PET is a molecular imaging modality that has demonstrated high sensitivity in the in vivo detection of glycolytic tissues, including tumors and inflammatory foci. 18F-FDG PET has been applied in a clinical setting to the assessment of inflammation for a variety of indications, including auto immune pancreatitis, atherosclerosis and infection. 18F-FDG-PET was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Here, SUVmax was standardized uptake values maximum and SUVmean was mean standardized uptake values were reported.
| gram/milliliter (g/ml) | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (DBTP) |
|---|---|---|
| SUVmax: Baseline | 2.318 ± 0.6168 | 2.738 ± 0.6027 |
| SUVmax: Change at Week 12 | 0.576 ± 1.0628 | 0.185 ± 0.5830 |
| SUVmean: Baseline | 1.212 ± 0.2513 | 1.478 ± 0.2000 |
| SUVmean: Change at Week 12 | 0.175 ± 0.2117 | -0.007 ± 0.2312 |
In DW-MRI the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 cubic millimeter (mm\^3). Normal pancreas ADCs were considered as (1.77±0.32)\*103 square-millimeters per second (mm\^2/sec) while acute pancreatitis ADCs were (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring projected inflammatory changes in pancreas. DW-MRI was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Change from baseline in degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab assessed by ADC was reported.
| Square-millimeters per second (mm^2/sec) | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (DBTP) |
|---|---|---|
| DBTP: Baseline | 0.00144 ± 0.000303 | 0.00154 ± 0.000257 |
| DBTP: Change at Week 12 | -0.00007 ± 0.000107 | 0.00001 ± 0.000133 |
In DW-MRI, the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 mm\^3. Normal pancreas ADCs were considered as (1.77±0.32)\*103 mm\^2/sec while acute pancreatitis ADCs are (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring the projected inflammatory changes in the pancreas. Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab assessed by ADC was reported.
| mm^2/sec | Evinacumab IV 15mg/kg Q4W (SBTP) |
|---|---|
| SBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC | -0.00001 ± 0.000166 |
Concentrations of total evinacumab in serum by time and DBTP treatment group reported
| milligram per liter (mg/L) | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (DBTP) |
|---|---|---|
| Week 0: Pre-Dose | NA ± NA | NA ± NA |
| Week 0: End Of Infusion | 24.3 ± 97.0 | 561 ± 203 |
| Week 4: Pre-Dose | NA ± NA | 73.6 ± 38.3 |
| Week 4: End of Infusion | 0.334 ± 1.25 | 590 ± 153 |
| Week 8: Pre-Dose | NA ± NA | 109 ± 57.2 |
| Week 8: End of Infusion | 28.8 ± 104 | 586 ± 119 |
| Week 12: Pre-Dose | 0.00639 ± 0.0239 | 124 ± 81.4 |
| Week 12: End Of Infusion | 544 ± 159 | 662 ± 146 |
| Week 20: Pre-Dose | 113 ± 51.9 | 160 ± 119 |
| Week 20: End Of Infusion | 675 ± 146 | 680 ± 199 |
| Week 24: Post Last Dose 4 Weeks | 121 ± 76.7 | 134 ± 77.2 |
| Week 28: Post Last Dose 8 Weeks | 43.1 ± 47.8 | 40.2 ± 44.6 |
| Week 36: Post Last Dose 16 Weeks | 0.239 ± 0.250 | 1.98 ± 7.41 |
| Week 44: Post Last Dose 24 Weeks | 0.0190 ± 0.0464 | 0.0680 ± 0.102 |
Concentrations of total ANGPTL3 in serum by time and DBTP treatment group reported
| mg/L | Placebo IV Q4W (DBTP) | Evinacumab IV 15mg/kg Q4W (DBTP) |
|---|---|---|
| Week 0: Pre-Dose | 0.0929 ± 0.0313 | 0.105 ± 0.0327 |
| Week 0: End of Infusion | 0.0950 ± 0.0256 | 0.258 ± 0.0745 |
| Week 4: Pre-Dose | 0.111 ± 0.0272 | 0.265 ± 0.0932 |
| Week 4: End of Infusion | 0.106 ± 0.0205 | 0.404 ± 0.132 |
| Week 8: Pre-Dose | 0.114 ± 0.0333 | 0.307 ± 0.0758 |
| Week 8: End of Infusion | 0.137 ± 0.0977 | 0.415 ± 0.0875 |
| Week 12: Pre-Dose | 0.107 ± 0.0273 | 0.310 ± 0.0911 |
| Week 12: End of Infusion | 0.250 ± 0.0940 | 0.394 ± 0.102 |
| Week 20: Pre-Dose | 0.302 ± 0.0973 | 0.346 ± 0.101 |
| Week 20: End of Infusion | 0.407 ± 0.144 | 0.422 ± 0.118 |
| Week 24: Post Last Dose 4 Weeks | 0.294 ± 0.0954 | 0.331 ± 0.113 |
| Week 28: Post Last Dose 8 Weeks | 0.311 ± 0.0701 | 0.265 ± 0.0984 |
| Week 36: Post Last Dose 16 Weeks | 0.134 ± 0.0487 | 0.193 ± 0.0969 |
| Week 44: Post Last Dose 24 Weeks | 0.107 ± 0.0322 | 0.131 ± 0.0489 |
ADA were classified as the following: 1) Negative any time (negative in ADA assay at all time points); 2) Pre-existing immunoreactivity (ADA positive response at baseline with all post treatment ADA results negative or ADA positive response at baseline with all post treatment responses less than 9-fold of baseline titer levels); 3) Treatment-boosted Response (ADA positive response in assay post first dose that is at least 9-fold over baseline titer levels, when baseline results were positive); 4) Treatment-emergent ADA response (ADA positive response post first dose, when baseline results were negative or missing). Number of participants with ADA by DBTP treatment group reported.
| Participants | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg IV (DBTP) |
|---|---|---|
| Negative any Time | 14 | 29 |
| Pre-existing Immunoreactivity | 1 | 4 |
| Treatment-boosted Response | 0 | 0 |
| Treatment-emergent Response | 0 | 1 |
TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the DBTP reported.
| Participants | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) |
|---|---|---|
| Participants with at least one TEAE | 11 | 25 |
| Participants with at least one serious TEAE | 3 | 4 |
TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the SBTP reported.
| Participants | Evinacumab 15 mg/kg (SBTP) |
|---|---|
| Participants with at least one TEAE | 38 |
| Participants with at least one Serious TEAE | 15 |
The number of participants with laboratory abnormalities in ALT, AST, ALP, and total bilirubin that fell into the pre-defined potentially clinically significant value (PCSV) categories reported: ALT: greater than (\>)2 upper limit of normal (ULN) and baseline (BL) less than or equal to (\<=) 2 ULN, less than (\>) 3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline ≤ 10 ULN, \>20 ULN and baseline \<= 20 ULN; AST: \>2 ULN and baseline ≤ 2 ULN, \>3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline \<= 10 ULN, \>20 ULN and baseline \<= 20 ULN; ALP: \> 1.5 ULN and baseline \<= 1.5 ULN; Total Bilirubin (TB): \> 1.5 ULN and baseline \<= 1.5 ULN, \> 2 ULN and baseline \<= 2 ULN.
| Participants | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Evinacumab 15 mg/kg (SBTP) |
|---|---|---|---|
| ALT >2 ULN and <=3 ULN and <=2 ULN at baseline | 0 | 1 | 0 |
| ALT >3 ULN and <=5 ULN and <=3 ULN at BL | 0 | 2 | 0 |
| ALT >5 ULN and <=10 ULN and <=5 ULN at BL | 0 | 0 | 2 |
| ALT 10 ULN and <=20 ULN and <=10 ULN at BL | 0 | 0 | 0 |
| ALT >20 ULN and <=20 ULN at BL | 0 | 0 | 0 |
| AST >2 ULN and <=3 ULN and <=2 ULN at BL | 0 | 2 | 0 |
| AST >3 ULN and <=5 ULN and <=3 ULN at BL | 0 | 1 | 1 |
| AST >5 ULN and <=10 ULN and <=5 ULN at BL | 0 | 0 | 1 |
| AST >10 ULN and <=20 ULN and <=10 ULN at BL | 0 | 0 | 0 |
| AST >20 ULN and <=20 ULN at BL | 0 | 0 | 0 |
| Bilirubin >1.5 ULN - <=2 ULN and =<1.5 ULN at BL | 0 | 0 | 0 |
| Bilirubin >2 ULN and =< 2.0 ULN at BL | 0 | 0 | 0 |
| Alkaline Phosphatase >1.5 ULN and =< 1.5 ULN at BL | 0 | 0 | 2 |
| (ALT>3ULN&TB>2ULN)&(ALT<=3ULN or TB<=2ULN) at BL | 0 | 0 | 0 |
Collected over From Day 1 up to Last Single-Blind (SB) dose + 168 days (24 weeks), up to approximately 44 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo IV Q4W (DBTP) | 0/16 (0%) | 3/16 (18.8%) | 11/16 (68.8%) |
| Evinacumab 15 mg/kg (DBTP) | 0/35 (0%) | 4/35 (11.4%) | 20/35 (57.1%) |
| Evinacumab 15 mg/kg (SBTP) | 0/15 (0%) | 4/15 (26.7%) | 13/15 (86.7%) |
| SBTP DB/SB Evinacumab IV 15mg/kg Q4W | 0/32 (0%) | 11/32 (34.4%) | 22/32 (68.8%) |
| Event | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Evinacumab 15 mg/kg (SBTP) | SBTP DB/SB Evinacumab IV 15mg/kg Q4W |
|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 2/16 | 3/35 | 4/15 | 8/32 |
| IleusGastrointestinal disorders | 0/16 | 0/35 | 1/15 | 0/32 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/16 | 0/35 | 1/15 | 0/32 |
| Abdominal painGastrointestinal disorders | 1/16 | 1/35 | 0/15 | 0/32 |
| Abdominal pain upperGastrointestinal disorders | 0/16 | 0/35 | 0/15 | 1/32 |
| Liver injuryHepatobiliary disorders | 0/16 | 0/35 | 0/15 | 1/32 |
| Clostridium difficile infectionInfections and infestations | 0/16 | 0/35 | 0/15 | 1/32 |
| Viral infectionInfections and infestations | 0/16 | 0/35 | 0/15 | 1/32 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/16 | 0/35 | 0/15 | 1/32 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/16 | 0/35 | 0/15 | 1/32 |
| Event | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Evinacumab 15 mg/kg (SBTP) | SBTP DB/SB Evinacumab IV 15mg/kg Q4W |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/16 | 4/35 | 2/15 | 4/32 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 1/35 | 2/15 | 0/32 |
| NauseaGastrointestinal disorders | 1/16 | 1/35 | 2/15 | 1/32 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/16 | 1/35 | 2/15 | 1/32 |
| HeadacheNervous system disorders | 2/16 | 4/35 | 2/15 | 2/32 |
| Alanine aminotransferase increasedInvestigations | 0/16 | 2/35 | 2/15 | 0/32 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 2/35 | 2/15 | 0/32 |
| Urinary tract infectionInfections and infestations | 1/16 | 0/35 | 1/15 | 4/32 |
| NasopharyngitisInfections and infestations | 1/16 | 2/35 | 1/15 | 3/32 |
| Abdominal pain upperGastrointestinal disorders | 0/16 | 1/35 | 1/15 | 3/32 |
The full analysis set (FAS) included all randomized participants who received any double-blind study drug based on the treatment assigned (as randomized).
| Age, Continuous(years) | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Total |
|---|---|---|---|
| Mean | 46.2 ± 13.10 | 48.6 ± 10.23 | 47.8 ± 11.13 |
| Sex: Female, Male(Participants) | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Total |
|---|---|---|---|
| Female | 7 | 17 | 24 |
| Male | 9 | 18 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 6 |
| Not Hispanic or Latino | 14 | 31 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 5 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 12 | 29 | 41 |
| Other | 3 | 0 | 3 |
| Fasting Triglycerides(milligrams/deciliter (mg/dL)) | Placebo IV Q4W (DBTP) | Evinacumab 15 mg/kg (DBTP) | Total |
|---|---|---|---|
| Mean | 2303.8 ± 1503.81 | 2475.1 ± 1597.20 | 2421.4 ± 1555.50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Dec 2019, 18 months.
Results were first posted in Feb 2023, 3 years 1 month after primary completion. A results delay was requested in Dec 2020.
Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evinacumab